Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage
暂无分享,去创建一个
S. Roman-Roman | F. Tirode | M. Stern | A. Constantinou | S. Piperno-Neumann | S. Alsafadi | Emilie Henry | M. Wassef | M. Dutertre | T. Popova | A. Battistella | Alexandre Houy | M. Stern | T. Popova
[1] M. Warmuth,et al. Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. , 2015, Cell reports.
[2] Dennis Carson,et al. Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3’ Splice Site Selection in SF3B1-mutated Cancers , 2015, PLoS Comput. Biol..
[3] Wilfried Haerty,et al. Genome-wide discovery of human splicing branchpoints , 2015, Genome research.
[4] Caterina Marchiò,et al. SF3B1 mutations constitute a novel therapeutic target in breast cancer , 2014, The Journal of pathology.
[5] A. Nicolas,et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target , 2014, Molecular oncology.
[6] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[7] Yi Zhang,et al. Mechanisms for U2AF to define 3′ splice sites and regulate alternative splicing in the human genome , 2014, Nature Structural &Molecular Biology.
[8] R. Halaban,et al. Rare SF3B1 R625 mutations in cutaneous melanoma , 2014, Melanoma research.
[9] S. Roman-Roman,et al. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages , 2014, Leukemia.
[10] Jian Zhang,et al. Misregulation of pre-mRNA alternative splicing in cancer. , 2013, Cancer discovery.
[11] David Gentien,et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. , 2013, Cancer discovery.
[12] A. Hinnebusch,et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3 , 2013, Nature Genetics.
[13] Cole Trapnell,et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.
[14] A. Bowcock,et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma , 2013, Nature Genetics.
[15] J. Valcárcel,et al. The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.
[16] E. Giné,et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.
[17] A. Sivachenko,et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.
[18] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[19] H. Tsoi,et al. Perturbation of U2AF65/NXF1-mediated RNA nuclear export enhances RNA toxicity in polyQ diseases. , 2011, Human molecular genetics.
[20] J. Valcárcel,et al. Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. , 2011, Genes & development.
[21] Christopher W. J. Smith,et al. Genome-Wide Association between Branch Point Properties and Alternative Splicing , 2010, PLoS Comput. Biol..
[22] C. Béroud,et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.
[23] C. Will,et al. The Spliceosome: Design Principles of a Dynamic RNP Machine , 2009, Cell.
[24] M. Carmo-Fonseca,et al. In Vivo Requirement of the Small Subunit of U2AF for Recognition of a Weak 3′ Splice Site , 2006, Molecular and Cellular Biology.
[25] Andrew M. MacMillan,et al. Crystal structure of a core spliceosomal protein interface , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[26] G. Crooks,et al. WebLogo: a sequence logo generator. , 2004, Genome research.
[27] Hiroki Inui,et al. Two essential splice lariat branchpoint sequences in one intron in a xeroderma pigmentosum DNA repair gene: mutations result in reduced XPC mRNA levels that correlate with cancer risk. , 2003, Human molecular genetics.
[28] Michael R. Green,et al. Functional recognition of the 3′ splice site AG by the splicing factor U2AF35 , 1999, Nature.
[29] J. Valcárcel,et al. Evidence for Substrate-Specific Requirement of the Splicing Factor U2AF35 and for Its Function after Polypyrimidine Tract Recognition by U2AF65 , 1999, Molecular and Cellular Biology.
[30] Or Gozani,et al. A Potential Role for U2AF-SAP 155 Interactions in Recruiting U2 snRNP to the Branch Site , 1998, Molecular and Cellular Biology.
[31] P. Norton,et al. Polypyrimidine tract sequences direct selection of alternative branch sites and influence protein binding. , 1994, Nucleic acids research.
[32] J. Valcárcel,et al. Dual Function for U2AF 35 in AG-Dependent Pre-mRNA Splicing , 2001 .